Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 7/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8034262 | 0.83 | PTGS1 (0.37) | KDM4EHPGDDHODHPARP1ALOX12 | |
| SCHEMBL3734379 | 0.83 | DHODH (0.45) | L3MBTL1DHODHPARP1 | |
| SCHEMBL11327139 | 0.82 | DUSP5 (0.35) | KDM4EHPGDDHODHPARP1 | |
| Silver SCHEMBL9320049 | 0.82 | PARP1 (0.33) | KDM4EHPGDDHODHPARP1 | |
| SCHEMBL6574358 | 0.81 | L3MBTL1 (0.57) | L3MBTL1TTRKDM4EHPGDDHODH | |
| SCHEMBL11234305 | 0.79 | PARP1 (0.53) | L3MBTL1KDM4EDHODHPARP1 | |
| SCHEMBL39083 | 0.76 | DHODH (0.61) | DHODHPARP1 | |
| SCHEMBL9394277 | 0.76 | PSMB8 (0.56) | L3MBTL1TTRKDM4EHPGDDHODH | |
| SCHEMBL6519737 | 0.76 | ALDH1A1 (0.42) | L3MBTL1TTRKDM4EHPGDDHODH | |
| SCHEMBL8712895 | 0.76 | FEN1 (0.41) | KDM4ECOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428545-B2 | Process for isolation of plasma or serum proteins | THERAPURE BIOPHARMA INC. (CA) | 2016-08-30 | — | — | US | claimed |
| US-20160128944-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME THERAPEUTICS LIMITED (IN) | 2016-05-12 | — | — | US | claimed |
| EP-3003031-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | Vyome Biosciences Pvt Ltd (IN) | 2016-04-13 | — | — | EP | claimed |
| CN-105407718-A | Coated particles and compositions comprising the same | VYOME BIOSCIENCES | 2016-03-16 | — | — | CN | claimed |
| US-20160009757-A1 | PROCESS FOR ISOLATION OF PLASMA OR SERUM PROTEINS | THERAPURE BIOPHARMA INC. (CA) | 2016-01-14 | — | — | US | claimed |
| WO-2014195872-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME BIOSCIENCES PVT. LTD. (IN) | 2014-12-11 | — | — | WO | claimed |
| EP-1765866-B1 | ISOLATION OF PLASMA OR SERUM PROTEINS | THERAPURE BIOPHARMA INC (CA) | 2014-01-08 | — | — | EP | claimed |
| EP-2788006-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4674856-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4635481-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4218722-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-4699873-A | HYDRAZINE DERIVATIVE COMPOUND AND DISULFIDE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1987-10-13 | — | — | US | disclosed |
| US-4681836-A | RHODIUM SALT, HYDRAZINE DERIVATIVE | FUJI PHOTO FILM CO., LTD. (JP) | 1987-07-21 | — | — | US | disclosed |
| EP-0196626-A2 | Silver halide photographic material and method for forming an ultrahigh contrast negative image therewith | FUJI PHOTO FILM CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| EP-0154293-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1985-09-11 | — | — | EP | disclosed |
| EP-0138200-A2 | Silver halide photographic material and method for forming high contrast negative image using the same | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-4332878-A | USING A HYDROQUINONE DERIVATIVE IN THE SILVER HALIDE EMULSION LAYER AND DEVELOPING IN THE PRESENCE OF A HYDRAZINE COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
| US-4323643-A | HIGH CONTRAST USING UREIDO ARYLHYDRAZIDE COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TTR 1516/4885KDM4E 4402/4885 |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TTR 1516/4885KDM4E 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.